Tumour necrosis factor alpha and the cardiovascular system: Its role in cardiac allograft rejection and heart disease

Cardiovascular Research

Volumn 43, Issue 4, 1999, Pages 850-859

  Azzawi, May ^a   Hasleton, Philip ^a  

^a Department of Pathology   (United Kingdom)

Author keywords

Atherosclerosis; Heart failure; Human; Myocardium; Rejection

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

CORONARY ARTERY DISEASE; CYTOKINE RELEASE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CALCIUM; CARDIOVASCULAR SYSTEM; CORONARY DISEASE; GRAFT REJECTION; HEART DISEASES; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032884448     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00138-8     Document Type: Review

References (120)

1. Saxne T., Palladino M.A. Jr., Heinegar D., et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis, synovial fluid and serum. Arthritis Rheum. 31:1988;1041-1045.
2. Sharief M.K., Hentges R. Association between tumor necrosis factor and disease progression in patients with Multiple Sclerosis. New Eng J Med. 325:1991;467-472.
3. Natanson C., Eichenholz P.W., Danner R.L., et al. Endotoxin and tumor necrosis factor challenges in dogs stimulate the cardiovascular profile in human septic shock. J Exp Med. 169:1989;823-832.
4. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of TNFα in severe chronic heart failure. New Eng J Med. 223:1990;236-241.
5. Arbustini E., Grasso M., Diegole M., et al. Expression of TNFα in human acute cardiac rejection. Am J Pathol. 139:1991;709-715.
6. Carswell E.A., Old L.J., Kassel R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci. 72:1975;3666-3670.
7. Gordon H.M., Kucera G., Salvo R., et al. TNF induces genes involved in inflammation, cellular and tissue repair, and metabolism in murine fibroblasts. J Immunol. 148:1992;4021-4027.
8. Hlodan R., Pain R.H. The folding and assembly pathway of TNFα, a globular trimeric protein. Eur J Biochem. 231:1995;381-387.
9. Torre-Amione G., Kapadia S., Lee J., et al. Expression and functional significance of TNF receptors in human myocardium. Circulation. 92:1995;1487-1493.
10. Chensue S.W., Remick D.G., Shmyr-Forsch C., et al. Immunohistochemical demonstration of cytoplasmic and membrane associated TNF in murine macrophages. Am J Pathol. 133:1988;564-572.
11. Kapadia S., Lee J.R., Torre-Amione G., et al. TNF gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest. 96:1995;1042-1052.
12. Crabtree G.R. Contingent genetic regulatory events in T Lymphocyte activation. Science. 243:1989;355-358.
13. English K., Weaver W.M., Wison C.B. Differential regulation of lymphotoxin and TNF genes in human T lymphocytes. J Biol Chem. 266:1991;7108-7113.
14. Goldfeld A.E., McCaffrey P.G., Strominger J.L., Rao A. Identification of a novel cyclosporin-sensitive element in the human TNF gene promoter. J Exp Med. 178:1993;1365-1379.
15. Rhoades K.L., Cai S.J., Golub S.H., Economou J.S. GM-CSF and IL-4 differentially regulate the human TNFα promoter region. Cell Immunol. 161:1995;125-131.
16. Caput D., Beutler B., Hartog K., et al. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 83:1986;1670-1674.
17. Shaw G., Kamen R.A. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 46:1986;659-667.
18. Han J., Huez G., Beutler B. Interactive effects of the TNF promoter and 3′-untranslated regions. J Immunol. 146:1991;1843-1848.
19. Leiberman A.P., Pitha P.M., Shin M.L. Poly A removal is the kinase regulated step in TNF mRNA decay. J Biol Chem. 267:1992;2123-2126.
20. Kruys V., Abdelaziz S., Huez G. Identification of protein binding TNFα mRNA UA-rich sequence, disruption of the interaction correlated with TNFα synthesis. Eur Cytokine Netw. 5:1994;144-146.
21. Giroir B.P., Johnson J.H., Brown T., et al. The tissue distribution of TNF biosynthesis during endotoxemia. J Clin Invest. 90:1992;693-698.
22. Tovey M.G., Content J., Gresser I., et al. Genes for IFN beta 1 (IL-6), TNF, and IL-1 are expressed at high levels in the organs of normal individuals. J Immunol. 141:1988;3106-3110.
23. Jacob C.O., Fronek Z., Lewis G.D., et al. Heritable major histocompatibility complex class II associated differences in production of TNFα: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA. 87:1990;1233-1238.
24. Pociot F., Briant L., Jongeneel C.V., et al. Association of TNFα and class II major histocompatibility complex alleles with the secretion of TNFα and TNFβ by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 23:1993;224-228.
25. Turner D.M., Williams D.M., Sankaran D., et al. An investigation of polymorphism in the IL-10 gene promoter. Eur J Immunogen. 24:1997;1-8.
26. Awad M.R., Turner D.M., Sinnott P.J., Hutchinson I.V. Polymorphisms in the TGF beta1 gene. Eur J Immunogen. 24:1997;45.
27. Turner D.M., Sankaran D., Grant S.C.D., et al. TNF-A and IL-10 gene polymorphism and heart transplant rejection. Eur J Immunogen. 24:1997;67.
28. Udalova I.A., Nedospasov S.A., Webb G.C., et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 16:1993;180-184.
29. Wilson A.G., deVries N., Pociot F., et al. An allelic polymorphism within the human TNFα promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 177:1993;557-561.
30. Wilson A.G., Symons J.A., McDowell T.L., et al. Effects of a TNFα promoter base transition on transcriptional activity. Br J Rheumatol. 33:(1):1994;89.
31. Hamann A., Mantzoros C., Vidalpuig A., Flier J.S. Genetic variability in the TNF promoter is not associated with type II diabetes mellitus. Biochem Biophys Res Commun. 211:1995;833-839.
32. Brinkman B.M.N., Kaijzel E.L., Huizinga T.W.J., et al. Detection of a C-insertion polymorphism within the human TNF A gene. Human Genet. 96:1995;493-496.
33. Finkel M.S., Oddis C.V., Jacob T.D., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
34. Mann D.L. The effect of TNFα on cardiac structure and function: A tale of two cytokines. J Cardiac Failure. 2:1996;S165-S172.
35. Schreiner G.F. Immune modulation of cardiac cell function. Trans Am Clin Climatol Assoc. 109:1998;39-49.
36. Oral H., Kapadia S., Nakano M., et al. TNFα and the failing human heart. Clin Cardiol. 18:1995;IV20-IV27.
37. Piano M.R., Bondmass M., Schwertz D.W. The molecular and cellular pathophysiology of heart failure. Heart Lung. 27:1998;3-19.
38. Nakamura K., Fushimi K., Kouchi H., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 98:1998;794-799.
39. Ono K., Matsumori A., Shioi T., Furukawa Y., Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation. 98:1998;149-156.
40. Pulkki K.J. Cytokines and cardiomyocyte death. Ann Med. 29:1997;339-343.
41. Walley K.R., Hebert P.C., Wakai Y., et al. Decrease in left ventricular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol. 76:1994;1060-1067.
42. Ceconi C., Curello S., Bachetti T., Corti A., Ferrari R. Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? Prog Cardiovasc Dis. 48:1998;25-30.
43. Panas D., Khadour F.H., Szabo C., Schulz R. Proinflammatory cytokines depress cardiac efficiency by a nitric oxide-dependent mechanism. Am J Physiol. 275:1998;H1016-H1023.
44. Edmunds N.J., Woodward B. Effects of tumour necrosis factor-alpha on the coronary circulation of the rat isolated perfused heart: a potential role for thromboxane A2 and sphingosine. Br J Pharmacol. 124:1998;493-498.
45. Yokoyama T., Vaca L., Rossen R.D., et al. Cellular basis for the negative inotropic effects of TNFα in the adult mammalian heart. J Clin Invest. 92:1993;2303-2312.
46. Cannon P.J., Yang X., Szabolcs M.J., et al. The role of inducible nitric oxide synthase in cardiac allograft rejection. Cardiovasc Res. 38:1998;6-15.
47. Oral H. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 272:1997;4836-4842.
48. Muller-Werdan U., Schumann H., Fuchs R., et al. Tumor necrosis factor alpha is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol. 29:1997;2915-2923.
49. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol. 274:1998;R577-R595.
50. Bozhurt B., Kribbs S.B., Clubb F.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97:1998;1382-1391.
51. Billingham M.E., Nathaneil R.B., Carey N.R.B., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart Transpl. 9:1990;587-593.
52. Alexander D.Z., Pearson T.C., Hendrix R., et al. Analysis of effector mechanisms in murine cardiac allograft rejection. Transpl Immunol. 4:1996;46-48.
53. Kaye M.P. The registry of the international society for heart and lung transplantation: ninth official report-1992. J Heart Lung Transpl. 4:1992;599-606.
54. Fishbein M.C., Bell G., Lones M.A., et al. Grade 2 cellular heart rejection: does it exist. J Heart Lung Transpl. 13:1994;1051-1057.
55. Winters G.L., McManus B.M. Consistencies and controversies in the application of the international society for the heart and lung transplantation working formulation for heart transplant biopsy specimens. J Heart Lung Transpl. 15:1996;728-735.
56. Hutchinson I.V. Immune mechanisms of long-term graft acceptance. Adv Nephrol. 25:1996;17-37.
57. Pober J.S., Cotran R.S. The role of endothelial cells in inflammation. Transpl. 50:1990;537-540.
58. Chollet-Martin S., Depoix J.P., Hvass Y., et al. Raised plasma levels of TNF in heart allograft rejection. Transplant Proc. 22:1990;283-285.
59. Maury C.P.J., Teppo A.M. Raised serum levels of cachectin/tumor necrosis factor in renal allograft rejection. J Exp Med. 166:1987;1132-1136.
60. Mclaughlin P.J., Aikawa A., Davies H.M., et al. Evaluation of sequential plasma and urinary tumour necrosis factor levels in renal allograft recipients. Transpl. 51:1991;1225-1228.
61. Imagawa D.K., Millis J.M., Olthoff K.M., et al. The role of TNFα in allograft rejection I: Evidence that elevated levels of TNFα predict rejection following orthotopic liver transplantation. Transpl. 50:1990;219-225.
62. Imagawa D.K., Millis J.M., Olthoff K.M., et al. The role of TNFα in allograft rejection II evidence that antibody therapy against TNFα and lymphotoxin enhances cardiac allograft survival in rats. Transpl. 50:1990;189-193.
63. Lin H., Chensue S.W., Strieter R.M., et al. Antibodies against tumour necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transpl. 11:1992;330-335.
64. Stevens H.P.J.D., vanderKwast T.H., vanderMeide P.H., et al. Synergistic immunosuppression effects of monoclonal antibodies specific for interferon-gamma and TNFα: a skin transplantation study in the rhesus monkey. Transpl. 50:1990;856-859.
65. Azzawi M., Grant S.C.D., Hasleton P.S., et al. TNFα mRNA and protein in cardiac transplant biopsies; comparison with serum TNFα levels. Cardiovasc Res. 32:1996;551-556.
66. Vandenbroecke C., Caillat-Zucman S., Legendre C., et al. Differential in situ expression of cytokines in renal allograft rejection. Transpl. 51:1991;602-609.
67. Noronha I.L., Eberlein-Gonka M., Hartley B., et al. In situ expression of TNFα, IFN gamma, and IL-2 receptors in renal allograft biopsies. Transpl. 54:1992;1017-1024.
68. Abdallah A.N., Billes M.A., Attia Y., et al. Evaluation of plasma levels of tumor necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J. 18:1997;1024-1029.
69. Jordan S.C., Czer L., Toyoda M., et al. Serum cytokine levels in heart allograft recipients: correlation with findings on endomyocardial biopsy. J Heart Lung Transpl. 12:1993;333-337.
70. Grant SCD. Cytokines and cardiac transplantation. M.D. Thesis, 1995, University of Leeds.
71. Grant S.C.D., Lamb W.R., Hutchinson I.V., Brenchley P.E.C. Serum soluble adhesion molecules and cytokines in cardiac allograft rejection. Transpl Immunol. 2:1994;321-325.
72. Torre-Amione G., MacLellan W., Kapadia S., et al. Tumor necrosis factor-alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transpl Proc. 30:1998;875-877.
73. Debets J.M.H., Leunissen K.M.L., VanHooff H.J., et al. Evidence of involvement of TNF in adverse reactions during treatment of kidney allograft rejection with antithymocyte globulin. Transpl. 47:1989;487-492.
74. Grant S.C.D., Lamb W.R., Gallati H., et al. Release of TNFα, IL-6, and the TNF receptors p55 and p75 following ATG therapy in heart and heart/lung transplant recipients. J Heart Lung Transpl. 12:1993;S72.
75. Serrick C., Adoumie R., Giaid A., Shennib H. The early release of interleukin-2, tumor necrosis factor and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transpl. 58:1994;1158-1162.
76. Meldrum D.R., Meng X., Dinarello C.A., et al. Human myocardial tissue TNF expression following acute global ischemia in vivo. J Mol Cell Cardiol. 30:1998;1683-1689.
77. Nakhleh R.E., Jones J., Goswitz J.J., et al. Correlation of EMB findings with autopsy findings in human cardiac allografts. J Heart Lung Transpl. 11:1992;479-485.
78. Sharples L.D., Cary N., Large S.R., Wallwork J. Error rates with which EMB specimens are graded for rejection after cardiac transplantation. Am J Cardiol. 70:1992;527-530.
79. Stovin P.G.I. Monitoring of cardiac rejection by endomyocardial biopsy. Wallwork J. Heart and heart lung transplantation. 1989;313-340 WB, Philadelphia.
80. Turner D.M., Grant S.C.D., Lamb W.R., et al. A genetic marker of high TNFα production in heart transplant recipients. Transpl. 60:1995;1113-1117.
81. Turner D.M., Grant S.C.D., Yonan N., et al. Cytokine gene polymorphism and heart transplant rejection. Transpl. 64:1997;776-779.
82. Morin L., SchlaepferI R., EckelA H. Tumour necrosis factor-alpha eliminates binding of NF-Y and octamer-binding protein to the lipoprotein lipase promotor in 3T 3-Ll adipocytes. J Clin Invest. 95:1995;1684-1689.
83. Feingold K.R., Grunfeld C. Role of cytokines in inducing hyperlipidaemia. Diabetes. 41:(suppl. 2):1992;97-101.
84. Starnes H.R. Jr., Warren R.S., Jeevanadem M., et al. Tumor necrosis factor and the acute metabolic response to injury in man. J Clin Invest. 82:1998;1321-1325.
85. HotamisligilG S., Peraldi P., Budavari A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science. 271:1996;665-668.
86. Nawroth P.P., Stem D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 163:1986;740-745.
87. Barath P., Fishbein M.C., Cao J., et al. Detection and localisation of tumor necrosis factor in human atheroma. Am J Cardiol. 65:1990;297-302.
88. Barath P., Fishbein M.C., Cao J., et al. Tumour necrosis factor gene expression in human vascular, intimal smooth muscle cells detected by in situ hybridisation. Am J Pathol. 137:1990;503-509.
89. Arbustini E., Grasso M., Diegoli M., et al. Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: A morphologic, immunohistochemical and biochemical study. Am J Cardiol. 68:1991;36B-50B.
90. Rayment N.B., Moss E., Faulkner L., et al. Synthesis of TNFα and TGFβ mRNA in the different micro-environments in atheromatous plaques. Cardiovasc Res. 32:1996;1123-1130.
91. Filonzi E.L., Zoellner H., Stanton H., Hamilton J.A. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 99:1993;241-252.
92. Tipping P.G., Hancock W.W. Production of tumour necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol. 142:1993;1721-1728.
93. Herrmann S.-M., Ricard S., Nicaud V., et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary artery disease and obesity. Eur J Invest. 28:1998;59-66.
94. Weidermann C.J., Weidermann F.J., Herold M., et al. Plasma levels of atrial naturetic peptide and tumor necrosis factor-alpha during transient myocardial ischaemia in patients with stable angina. Klin Wochenschr. 69:1991;944.
95. Clausell N., CorreadeLima V.C., Molossi S., et al. Expression of tumour necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J. 73:1995;534-539.
96. Molossi S., Clausell N., Rabinovitch N. Reciprocal induction of tumour necrosis factor-alpha and interleukin-1 beta activity mediate fibronectin synthesis in coronary artery smooth muscle cells. J Cell Physiol. 163:1995;19-29.
97. Clausell N., Molossi S., Sett S., Rabinovitch N. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits following cardiac transplant inhibits acute coronary artery neo-intimal formation. Circulation. 89:1994;2768-2779.
98. Deng M.C., Dasch B., Erren M., Mollhoff T., Scheld H.H. Impact of left ventricular dysfunction on cytokines, hemodynamic, and outcome in bypass grafting. Ann Thorac Surg. 62:1996;184-190.
99. Menasche P., Haydur S., Peynet J., et al. A potential mechanism of vasodilatation after heart surgery. The temperature dependant release of cytokines. J Thorac Cardiovasc Surg. 107:1994;293-299.
100. Haeffner-Cavaillon N., Roussellier N., Ponzio O., et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 98:1989;1100-1106.
101. Steinberg J.B., Kapelanski D.P., Olson J.D., Weiler J.M. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 106:1993;1008-1016.
102. Deng M.C., Wiedner M., Erren M., et al. Arterial and venous cytokine response to cardiopulmonary bypass for the low risk CABG and relation to hemodynamics. Eur J Cardiothorac Surg. 9:1995;22-29.
103. Millar A.B., Armstrong L., van der Linden J., et al. Cytokine production and hemofiltration in children undergoing cardiopulmonary bypass. Am Thorac Surg. 56:1993;1499-1502.
104. Butler J., Pillai R., Rocker G.M., et al. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg. 105:1993;25-30.
105. Wan S., DeSmet J.-M., Barvais L., et al. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 112:1996;806-811.
106. Maury C.P., Teppo A.-M. Circulating tumor necrosis factor-alpha (cachectin) in myocardial infarction. J Int Med. 225:1989;333-336.
107. Hasleton P.S. Spencer's pathology of the lung. 5th Edn :1996;377-379 McGraw Hill.
108. Katz S.D., Rao R., Berman J.W., et al. Pathophysiological correlates of increased serum TNF in patients with congestive heart failure. Circulation. 90:1994;12-16.
109. Ferrari R. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res. 37:1998;554-559.
110. Blum A., Miller H. Role of cytokines in heart failure. Am Heart J. 135:1998;181-186.
111. Nakano M., Knowlton A.A., Dibbs Z., Mann D.L. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation. 97:1998;1392-1400.
112. Habib F.M., Springall D., Davies G.J., et al. Tumor necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet. 347:1996;1151-1155.
113. Kroncke K.-D., Fesel K., Kolb-Bachofen V. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol Chem Hoppe-Seyler. 376:1995;327-343.
114. Matsumori A., Yamada T., Suzuki H., Matoba Y., Sasayama S. Increased circulating cytokines in myocarditis and cardiomyopathy. Br Heart J. 72:1994;561-566.
115. Matsmori A., Hirose K., Wakabayashi A., et al. HL-A and hypertrophic cardiomyopathy. Am Heart J. 97:1979;428-431.
116. Matsmori A., Wakabayashi A., Teraski P.l., et al. HLA-DRW4 antigen linkage in patients with hypertrophic obstructive cardiomyopathy. Am Heart J. 101:1981;14-16.
117. Carlquist J.F., Menlove R.L., Murray M.B., O'Connell J.B., Anderson J.L. HIA class 11 (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis have published HLA association studies. Circulation. 83:1991;515-522.
118. Kubota T., McNamara D.M., Wang J.J., et al. Effects of tumor necrosis factor gene polymorphs on patients with congestive heart failure. Circulation. 97:1998;2499-2501.
119. Meldrum D.R., Dinarello C.A., Cleveland J.C., et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 124:1998;291-296.
120. Meldrum D.R., Cain B.S., Cleveland J.C., et al. Adenosine decreases post-ischaemic cardiac TNF production: anti-inflammatory implications for preconditioning and transplantation. Immunology. 92:1997;472-477.